Janssen buys autoimmune licence from Novo Nordisk
22 May 2015 | News | By BioSpectrum Bureau
Janssen buys autoimmune licence from Novo Nordisk
Terms of the agreement have not been disclosed
Novo Nordisk A/S has signed an agreement with Janssen Biotech (Janssen) under which Janssen will acquire an exclusive global licence to further develop and commercialise a clinical programme focused on therapy within autoimmune diseases. The programme targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement have not been disclosed.
The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the US Department of Justice Antitrust Division and the Federal Trade Commission.
